Intravenous immunoglobulin for the treatment of childhood encephalitis
Encephalitis is a syndrome of neurological dysfunction due to inflammation of the brain parenchyma, caused by an infection or an exaggerated host immune response, or both. Attenuation of brain inflammation through modulation of the immune response could improve patient outcomes. Biological agents su...
Prif Awduron: | Iro, M, Martin, N, Absoud, M, Pollard, A |
---|---|
Fformat: | Journal article |
Iaith: | English |
Cyhoeddwyd: |
Cochrane Collaboration
2017
|
Eitemau Tebyg
-
Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial
gan: Hill, M, et al.
Cyhoeddwyd: (2023) -
Childhood encephalitis in the United Kingdom - epidemiology, trends in hospital admissions and the role of intravenous immunoglobulin
gan: Iro, M
Cyhoeddwyd: (2018) -
Intravenous immunoglobulin treatment for encephalitis in children aged 6 months to 16 years: the IgNiTE RCT
gan: Iro, MA, et al.
Cyhoeddwyd: (2024) -
Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial
gan: Simon Nadel, et al.
Cyhoeddwyd: (2023-11-01) -
Intravenous immunoglobulin treatment for encephalitis in children aged 6 months to 16 years: the IgNiTE RCT
gan: Mildred A Iro, et al.
Cyhoeddwyd: (2024-04-01)